IL298542B2 - Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their salts - Google Patents

Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their salts

Info

Publication number
IL298542B2
IL298542B2 IL298542A IL29854222A IL298542B2 IL 298542 B2 IL298542 B2 IL 298542B2 IL 298542 A IL298542 A IL 298542A IL 29854222 A IL29854222 A IL 29854222A IL 298542 B2 IL298542 B2 IL 298542B2
Authority
IL
Israel
Prior art keywords
dimethyltryptamine
solid dosage
dosage form
compounds
disorder
Prior art date
Application number
IL298542A
Other languages
English (en)
Hebrew (he)
Other versions
IL298542B1 (en
IL298542A (en
Inventor
Rands Peter
Benway Tiffanie
Joel Zelah
Claire Layzell Marie
James Ellen
Original Assignee
Cybin Uk Ltd
Rands Peter
Benway Tiffanie
Joel Zelah
Claire Layzell Marie
James Ellen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/890,664 external-priority patent/US11771681B2/en
Priority claimed from US17/108,938 external-priority patent/US20220169606A1/en
Priority claimed from US17/108,679 external-priority patent/US20220168274A1/en
Priority claimed from GBGB2018955.1A external-priority patent/GB202018955D0/en
Priority claimed from GBGB2018950.2A external-priority patent/GB202018950D0/en
Priority claimed from GB2103981.3A external-priority patent/GB2605144A/en
Priority claimed from US17/208,583 external-priority patent/US11773062B2/en
Application filed by Cybin Uk Ltd, Rands Peter, Benway Tiffanie, Joel Zelah, Claire Layzell Marie, James Ellen filed Critical Cybin Uk Ltd
Publication of IL298542A publication Critical patent/IL298542A/en
Publication of IL298542B1 publication Critical patent/IL298542B1/en
Publication of IL298542B2 publication Critical patent/IL298542B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL298542A 2020-06-02 2021-05-13 Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their salts IL298542B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US16/890,664 US11771681B2 (en) 2019-06-03 2020-06-02 Therapeutic compounds
PCT/EP2020/065244 WO2020245133A1 (en) 2019-06-03 2020-06-02 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions
US17/108,938 US20220169606A1 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
US17/108,679 US20220168274A1 (en) 2020-12-01 2020-12-01 Parenteral Formulation
GBGB2018955.1A GB202018955D0 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
GBGB2018950.2A GB202018950D0 (en) 2020-12-01 2020-12-01 Parenteral formulation
GB2103981.3A GB2605144A (en) 2021-03-22 2021-03-22 Deuterated compounds
US17/208,583 US11773062B2 (en) 2021-03-22 2021-03-22 Deuterated compounds
PCT/EP2021/060750 WO2021116503A2 (en) 2020-06-02 2021-04-23 Deuterated compounds
PCT/EP2021/062794 WO2021244831A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms

Publications (3)

Publication Number Publication Date
IL298542A IL298542A (en) 2023-01-01
IL298542B1 IL298542B1 (en) 2024-10-01
IL298542B2 true IL298542B2 (en) 2025-02-01

Family

ID=76329655

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298542A IL298542B2 (en) 2020-06-02 2021-05-13 Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their salts

Country Status (8)

Country Link
EP (3) EP3902541B1 (cg-RX-API-DMAC7.html)
JP (1) JP7579888B2 (cg-RX-API-DMAC7.html)
CN (1) CN115996713A (cg-RX-API-DMAC7.html)
AU (1) AU2021284861B2 (cg-RX-API-DMAC7.html)
CA (1) CA3118556A1 (cg-RX-API-DMAC7.html)
GB (1) GB2595776B (cg-RX-API-DMAC7.html)
IL (1) IL298542B2 (cg-RX-API-DMAC7.html)
WO (2) WO2021116503A2 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HRP20220797T1 (hr) 2019-11-07 2022-10-14 Small Pharma Ltd Spojevi
AU2021215709A1 (en) 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
WO2022026223A1 (en) * 2020-07-29 2022-02-03 Gregory Ellis Delivery system for ayahuasca-like substances
JP2023539113A (ja) 2020-08-18 2023-09-13 サイビン アイアールエル リミテッド フェネチルアミン誘導体、組成物およびその使用方法
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP4255421A1 (en) 2020-12-01 2023-10-11 Small Pharma Ltd Inhalable formulations
EP4031529B1 (en) * 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
WO2022120181A1 (en) 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
EP4433049A1 (en) 2021-11-18 2024-09-25 Cybin UK Ltd Injectable and inhalable formulations
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
CA3238440A1 (en) * 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
MX2024008691A (es) * 2022-01-14 2024-07-19 Cybin Irl Ltd Composiciones y metodos de triptamina.
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
AU2023242469A1 (en) * 2022-03-31 2024-09-05 Cybin Irl Limited Combination of nitrous oxide and 5-ht2a receptor agonists
EP4522167A1 (en) 2022-05-10 2025-03-19 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS
WO2020245133A1 (en) * 2019-06-03 2020-12-10 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
HRP20220797T1 (hr) * 2019-11-07 2022-10-14 Small Pharma Ltd Spojevi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS
WO2020245133A1 (en) * 2019-06-03 2020-12-10 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEATON J M ET AL,, A COMPARISON OF THE BEHAVIORAL EFFECTS OF PROTEO- AND DEUTERO-N, N-DIMETHYLTRYPTAMINE, 1 May 1982 (1982-05-01) *
MORRIS ET AL.,, INDOLEALKYLAMINE METABOLISM: SYNTHESIS OF DEUTERATED INDOLEALKYLAMINES AS METABOLIC PROBES, 31 December 1993 (1993-12-31) *
SIMON D. BRANDT ET AL,, MICROWAVE-ACCELERATED SYNTHESIS OF PSYCHOACTIVE DEUTERATED N , N -DIALKYLATED-[ [ALPHA] , [ALPHA] , [BETA] , [BETA] -D 4 ]-TRYPTAMINES, 1 November 2008 (2008-11-01) *

Also Published As

Publication number Publication date
WO2021116503A8 (en) 2021-08-12
JP7579888B2 (ja) 2024-11-08
IL298542B1 (en) 2024-10-01
EP4494703A2 (en) 2025-01-22
GB202106881D0 (en) 2021-06-30
EP4149460A1 (en) 2023-03-22
EP4149460B8 (en) 2025-01-08
AU2021284861B2 (en) 2026-06-11
EP3902541B1 (en) 2022-09-14
EP4149460C0 (en) 2024-11-27
WO2021116503A2 (en) 2021-06-17
EP4494703A3 (en) 2025-04-02
IL298542A (en) 2023-01-01
EP3902541A2 (en) 2021-11-03
WO2021244831A1 (en) 2021-12-09
AU2021284861A1 (en) 2023-01-05
JP2023527575A (ja) 2023-06-29
CN115996713A (zh) 2023-04-21
EP4149460B1 (en) 2024-11-27
WO2021116503A3 (en) 2023-09-28
GB2595776B (en) 2023-05-24
CA3118556A1 (en) 2021-12-02
GB2595776A (en) 2021-12-08

Similar Documents

Publication Publication Date Title
IL298542B1 (en) Therapeutic solid dosage forms comprising deuterated n,n-dimethyltryptamine compounds and salts thereof
JP2023527575A5 (cg-RX-API-DMAC7.html)
JP2017203047A (ja) ノルイボガインのリン酸エステル
WO2017172795A1 (en) Novel compositions and methods
Riederer et al. Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia
EP0844875B1 (en) Use of basic l-carnitine and acyl derivatives for lowering ceramide levels
JP2017203046A (ja) ノルイボガインの硫酸エステル
JP2022526763A5 (cg-RX-API-DMAC7.html)
WO1998038999A1 (en) The use of levobupivacaine in paediatric surgery
AU2024413434A1 (en) Carbamoyl lipid having cyclic group at side chain, lipid nanoparticle thereof, and pharmaceutical composition thereof
JP2025509830A5 (cg-RX-API-DMAC7.html)
CA2165446C (en) Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade
TW200410683A (en) Medicament for preventing and/or treating peripheral neuropathies
RU99128026A (ru) Новая соль
JPH0755906B2 (ja) ジサツカライド誘導体含有鎮痛剤
IL298541B1 (en) 1,1-dideuterio-2-(1H-indol-3-yl)-N,N-bis(trideuteriomethyl)ethanamine and a medical preparation containing it
NZ794813B2 (en) Therapeutic solid dosage forms
US20130023535A1 (en) Method of preventing and/or treating diabetic neuropathy
NZ794813A (en) Therapeutic solid dosage forms
EP0429676B1 (en) Drug for improving brain function
WO2005105089A1 (ja) 精神神経疾患の治療薬
Ban Haloperidol and the butyrophenones
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
Hoffman et al. Cerebrovascular and cerebral metabolic effects of clurazepam and a benzodiazepine antagonist, 3-hydroxymethyl-β-carboline
NZ783166A (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds